Trials / Completed
CompletedNCT01987011
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers
Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 420 (actual)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.
Detailed description
MG1109 is purified, inactivated influenza viral antigen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MG1109 | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2013-10-01
- Completion
- 2014-03-01
- First posted
- 2013-11-19
- Last updated
- 2015-07-03
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01987011. Inclusion in this directory is not an endorsement.